We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Potential Biomarkers Found for Early Alzheimer's Diagnosis

By LabMedica International staff writers
Posted on 05 Nov 2013
The presymptomatic stage of Alzheimer’s disease (AD) occurs at least one decade before the clinical onset, highlighting the need for validated biomarkers that reflect this early period.

The success of future intervention strategies for AD will likely rely on the development of treatments, once a definitive diagnosis has been made early in the course of the disease, before irreversible brain damage occurs.

Scientists at Linköping University (Sweden) working with international collaborators, performed a targeted search for lysosomal network proteins in human cerebrospinal fluid (CSF). More...
They studied samples of spinal marrow from 20 Alzheimer's patients and an equal number of healthy control subjects. The screening was aimed at 35 proteins that are associated with the lysosomal network.

CSF levels of the core AD biomarkers, including Aβ1–42, T-tau and P-tau181P phosphorylated at threonine181, were determined using INNOTEST enzyme linked immunosorbent assay (ELISA) kits (Innogenetics; Ghent, Belgium). Albumin levels were measured by immunonephelometry on a Beckman Image Immunochemistry system (Beckman Instruments, Beckman Coulter; Brea, CA, USA). Western blots were performed on CSF samples and immunodetection of the bound antibodies was performed using Amersham ECL detection systems (GE Healthcare; Pittsburgh, PA, USA).

Of thirty-four candidate lysosomal network proteins, they found that only six proteins were increased, indicating that a specific subset of lysosomal network proteins is overexpressed in the CSF of AD patients. The scientists identified the six as the endosomal proteins rat sarcoma (ras) in the brain 3, (Rab3) andRab7; the early endosomal antigen 1 (EEA1); the lysosomal-associated membrane proteins 1 and 2 (LAMP-1, LAMP-2), and the autophagy microtubule-associated protein 1 light chain 3 (LC3) and all were significantly upregulated in the CSF of AD patients.

Katarina Kågedal, PhD, the lead author of the study said, “In victims of Alzheimer's, something happens to the lysosomes so that they can't manage to take care of the surplus of beta amyloid. They fill up with junk that normally is broken down into its component parts and recycled.” Her hope is that the group's discovery will contribute to early diagnoses of the illness, which is necessary in the first stage in order to be able to begin reliable clinical tests of candidates for drugs, but perhaps the six lysosomal proteins could also be targets for developing drugs. The study was published on October 8, 2013, in the journal Neuromolecular Medicine.

Related Links:

Linköping University
Innogenetics
Beckman Instruments 
 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.